FDA expands use of Gilead's liver drug to rare subset of patients

February 16, 2016 2:52 PM

10 0

FDA expands use of Gilead's liver drug to rare subset of patients

The U.S. Food and Drug Administration has expanded the use of Gilead Sciences Inc's blockbuster drug Harvoni to some hepatitis C patients in the advanced stage of cirrhosis, including those who have undergone liver transplant.

Chronic hepatitis C patients often develop scarring and poor liver function also known as cirrhosis, which can lead to complications such as bleeding, jaundice, fluid accumulation in the abdomen and liver cancer.

Also read: Senate Clears Bill to Ease FDA Drug and Device Approvals

Read more

To category page

Loading...